UPLOAD Filing
Galmed Pharmaceuticals Ltd.
Date: Aug. 20, 2025 · CIK: 0001595353 · Accession: 0000000000-25-008880
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289703
Letter
Re: Galmed Pharmaceuticals Ltd. Registration Statement on Form F-1 Filed August 18, 2025 File No. 333-289703 Dear Allen Baharaff:
August 20, 2025
Allen Baharaff Chief Executive Officer Galmed Pharmaceuticals Ltd. c/o Meitar Law Offices 16 Abba Hillel Silver Rd. Ramat Gan 5250608 Israel
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Gary Emmanuel, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 20, 2025 Allen Baharaff Chief Executive Officer Galmed Pharmaceuticals Ltd. c/o Meitar Law Offices 16 Abba Hillel Silver Rd. Ramat Gan 5250608 Israel Re: Galmed Pharmaceuticals Ltd. Registration Statement on Form F-1 Filed August 18, 2025 File No. 333-289703 Dear Allen Baharaff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel, Esq. </TEXT> </DOCUMENT>